Chemomab Therapeutics (CMMB) Other Non Operating Income (2019 - 2023)
Chemomab Therapeutics (CMMB) posted Other Non Operating Income of $317000.0 for Q1 2023, up 33.76% on a QoQ basis from $237000.0 in Q3 2022, and up 46.76% year-over-year from $216000.0 in Q1 2022.
Chemomab Therapeutics (CMMB) Other Non Operating Income (2019 - 2023) Analysis & Trends
Chemomab Therapeutics' Other Non Operating Income history runs 5 years deep, the most recent figure standing at $317000.0 for Q1 2023.
- Quarterly Other Non Operating Income rose 46.76% year-over-year to $317000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $290000.0 (up 163.64% YoY) and the FY2021 annual result came in at -$111000.0, down 628.57% from the prior year.
- Other Non Operating Income was $317000.0 for Q1 2023 at Chemomab Therapeutics, up from $237000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $4.5 million in Q1 2019 and bottomed at -$480000.0 in Q2 2022.
- A 5-year average of $309250.0 and a median of $14500.0 in 2020 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2021 — Other Non Operating Income tumbled 7800.0% — and 2022, when it soared 4420.0%.
- Chemomab Therapeutics' Other Non Operating Income stood at $60000.0 in 2019, then sank by 115.0% to -$9000.0 in 2020, then slumped by 33.33% to -$12000.0 in 2021, then surged by 2075.0% to $237000.0 in 2022, then surged by 33.76% to $317000.0 in 2023.
- Business Quant data shows CMMB's Other Non Operating Income at $317000.0 in Q1 2023, $237000.0 in Q3 2022, and -$480000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 317,000.00 |
| Sep 30, 2022 | 237,000.00 |
| Jun 30, 2022 | -480,000.00 |
| Mar 31, 2022 | 216,000.00 |
| Dec 31, 2021 | -12,000.00 |
| Sep 30, 2021 | -77,000.00 |
| Jun 30, 2021 | -17,000.00 |
| Mar 31, 2021 | -5,000.00 |
| Dec 31, 2020 | -9,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 20,000.00 |
| Mar 31, 2020 | 9,000.00 |
| Dec 31, 2019 | 60,000.00 |
| Sep 30, 2019 | 102,000.00 |
| Jun 30, 2019 | 99,000.00 |
| Mar 31, 2019 | 4.49 Mn |